Qual é o preço para Sesen Bio, Inc. (SESN)

O preço para Sesen Bio, Inc. (SESN) é $0.6288

Qual é a capitalização de mercado para Sesen Bio, Inc. (SESN)

A capitalização de mercado para Sesen Bio, Inc. (SESN) é $6.00M

Sesen Bio, Inc. (SESN) Dividendos

Sesen Bio, Inc. is a clinical-stage biotechnology firm deeply involved in the creation, advancement, and eventual market launch of targeted fusion protein therapeutics (TFPTs). Their primary aim is to combat various forms of cancer. Their flagship experimental drug, Vicineum, is a locally administered targeted fusion protein currently undergoing Phase III clinical trials. It targets several conditions, including non-muscle invasive bladder cancer that has not responded to bacillus Calmette-Guérin (BCG) treatment, non-muscle invasive carcinoma in situ of the bladder in patients who previously received BCG, and squamous cell carcinoma affecting the head and neck region. Another promising candidate, VB6-845d, is being developed to address a range of anti-epithelial cell adhesion molecule-positive solid tumors. Sesen Bio is also collaborating with Leiden University Medical Center on the joint development of an imaging agent. Originally incorporated in 2008, the company operated as Eleven Biotherapeutics, Inc. before rebranding as Sesen Bio, Inc. in May 2018. Its corporate headquarters are situated in Cambridge, Massachusetts.

Ano	Dividendo (ajustado para desdobramentos)	Alterar
Não há dados suficientes para as datas fornecidas.

Ano

Dividendo (ajustado para desdobramentos)

Alterar

Não há dados suficientes para as datas fornecidas.

Ano	Dividendo	Alterar
Não há dados suficientes para as datas fornecidas.

Ano

Dividendo

Alterar

Não há dados suficientes para as datas fornecidas.

Empresa	Número de pagamentos de dividendos	País
Vertex Pharmaceuticals Incorporated VRTX.US	0.00%	US
Argenx SE ARGX.US	0.00%	NL
Lonza Group AG LONN.SW	0.00%	CH
Samsung Biologics Co.,Ltd. 207940.KS	0.00%	KR
UCB S.A. UCB.BR	29.00%	BE

Empresa

Número de pagamentos de dividendos

País